company background image
AKBA

Akebia Therapeutics NasdaqCM:AKBA Stock Report

Last Price

US$0.63

Market Cap

US$115.9m

7D

-11.5%

1Y

-66.3%

Updated

01 Feb, 2023

Data

Company Financials +

Akebia Therapeutics, Inc.

NasdaqCM:AKBA Stock Report

Mkt Cap: US$115.9m

AKBA Stock Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

AKBA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Akebia Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Akebia Therapeutics
Historical stock prices
Current Share PriceUS$0.63
52 Week HighUS$2.93
52 Week LowUS$0.24
Beta0.88
1 Month Change9.19%
3 Month Change120.98%
1 Year Change-66.31%
3 Year Change-92.35%
5 Year Change-95.61%
Change since IPO-97.64%

Recent News & Updates

Recent updates

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10
Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Jun 24
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

May 26
Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?

Mar 31
Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?

Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?

Mar 10
Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?

Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?

Mar 10
Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?

Does Akebia Therapeutics (NASDAQ:AKBA) Have A Healthy Balance Sheet?

Nov 28
Does Akebia Therapeutics (NASDAQ:AKBA) Have A Healthy Balance Sheet?

Shareholder Returns

AKBAUS BiotechsUS Market
7D-11.5%-0.2%1.7%
1Y-66.3%3.9%-12.5%

Return vs Industry: AKBA underperformed the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: AKBA underperformed the US Market which returned -13.6% over the past year.

Price Volatility

Is AKBA's price volatile compared to industry and market?
AKBA volatility
AKBA Average Weekly Movement13.2%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: AKBA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AKBA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007426John Butlerhttps://www.akebia.com

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

Akebia Therapeutics, Inc. Fundamentals Summary

How do Akebia Therapeutics's earnings and revenue compare to its market cap?
AKBA fundamental statistics
Market CapUS$115.90m
Earnings (TTM)-US$155.69m
Revenue (TTM)US$297.03m

0.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AKBA income statement (TTM)
RevenueUS$297.03m
Cost of RevenueUS$213.82m
Gross ProfitUS$83.20m
Other ExpensesUS$238.89m
Earnings-US$155.69m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin28.01%
Net Profit Margin-52.42%
Debt/Equity Ratio476.0%

How did AKBA perform over the long term?

See historical performance and comparison